[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482011":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":50,"collaborators":53,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":30,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":30,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Barbara Ann Karmanos Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[18F]FETrp PET radiotracer","EXPERIMENTAL","All participants will receive the tracer to evaluate the uptake of \\[18F\\]FETrp PET\u002FCT on intra- and extracranial cancers.",[13],"Drug: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","1-(2-[18F]FLUOROETHYL)-L-Tryptophan","Radioactive tracer 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan 0.14mCi\u002Fkg\u002F5MBq\u002Fkg injection given one time prior to PET Scan.",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Csaba Juhasz, M.D.,Ph.D","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Csaba Juhasz, M.D., Ph.D","CONTACT","313-966-5136",null,"csaba.juhasz@wayne.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Karmanos Cancer Institute","RECRUITING","Detroit","Michigan","48201","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-83.04575,42.33143,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":29,"phoneExt":30,"email":31},"Csaba Juhasz, MD, PhD",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Csaba Juhasz","Principal Investigator",[54],{"name":55,"class":6},"Washington University School of Medicine","100482011","phase-1-f-tryptophan-petct-in-human-cancers-100482011",false,"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers","A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET\u002FCT Imaging In Human Cancers","Inclusion Criteria:\n\n* Age ≥18 years.\n* Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.\n* Patient is able to lie in the PET\u002FCT scanner for at least 70 minutes while undergoing scanning.\n* Women of childbearing potential must not be pregnant or breastfeeding.\n* Recent anatomic imaging with visible disease (tumor) for comparison with the PET\u002FCT. .\n* Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.\n\nInclusion Criteria Specific for Intracranial Tumors\n\n\\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.\n\nInclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.\n* ECOG performance status of 2 or better.\n* Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \\[LAR\\], depot) for \\>3 months before enrollment may be enrolled on the study, but such treatment is not required.\n\nInclusion Criteria specific for Extracranial Primary Breast tumors:\n\n* Clinical and radiological diagnosis of a breast cancer\n* ECOG performance status of 2 or better.\n\nInclusion Criteria specific for Rectal tumors:\n\n* Histologically confirmed colorectal cancer, which is located in the rectum.\n* ECOG performance status of 2 or better.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded.\n\nExclusion Criteria Specific for Intracranial Tumors:\n\n* Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.\n* Tumor surgery or radiation within 1 month prior to the PET scan\n\nExclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Tumor-directed therapy within 3 months to the area of planned imaging.\n* Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).\n* Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.\n\nExclusion Criteria for Extracranial Primary Breast tumors:\n\n-Recent (within 1 month) tumor resection or radio-chemotherapy (acute\u002Fsubacute post-treatment inflammatory changes may cause false positive increases on PET).\n\nExclusion Criteria for Rectal tumors:\n\n-Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.","ALL","18 Years",{"count":66,"type":67},24,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","Imaging procedures such as 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan PET\u002FCT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.",[73,74,75,76,77],"Intracranial Glioma","Metastatic Brain Tumor","Breast Cancer","Neuroendocrine Tumors","Rectal Cancer","2026-01-21",{"date":80,"type":81},"2026-01-23","ACTUAL",{"date":83,"type":81},"2022-09-29",{"date":85,"type":67},"2027-12-31",{"name":5,"class":6},1]